Haematology- November 2013

AttachmentSize
PDF icon Haematology November 2013.pdf360.58 KB

Contents

Cochrane Systematic Reviews. 

Acute Leukaemia. 

Anaemia. 

Antocoagulantsand Antiplatelet Drugs. 

Chronic Leukaemia. 

Haemophilia. 

Lymphoma. 

Miscellaneous. 

Myeloma / Multiple Myeloma.

Non-Hodgkin's Lymphoma.

Neutropenia / Febrile Neutropenia.

Other Infections.

Sickle Cell Anaemia & Thalassemia.

Thrombocytopenia.

VTE.

International Guidelines & Guideline-Related (During the Previous Year)

Recent NICE Guidelines  etc. (During the Previous Year)

New Books Available at HEFT Libraries.

HEFT Libraries- Good Hope, Heartlands and Solihull 

Cochrane Systematic Reviews

Gurion, R. Belnik-Plitman, Y. Gafter-Gvili, A. [et al]. (2012). Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia.Cochrane Database of Systematic Reviews (Online), June 13th 2013, Issue 6, No. CD008238. Full Text Link.

Muchtar, E. Vidal, L. Ram, R. [et al]. (2013). The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.Cochrane Database of Systematic Reviews (Online).March 28th2013; Issue 3: No.CD009594. Review.

 

Acute Leukaemia

Inaba, H. Greaves, M.Mullighan, CG. (2013). Acute lymphoblastic leukaemia.Lancet.June 1st2013;381(9881):1943-55. Review.Full Text Link.

Gupta, V. Richards, S. [and] Rowe, J.; Acute Leukemia Stem Cell Transplantation Trialists' Collaborative Group (2013).Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.Blood.January 10th2013;121(2):339-50. Full Text Link.

Cecinati, V. Principi, N. Brescia, L. [et al]. (2013). Antibiotic prophylaxis in children with cancer or who have undergone hematopoietic cell transplantation.European Journal of Clinical Microbiology and Infectious DiseasesJuly 26th2013. [Epub ahead of print].

Pleyer, L. Stauder, R. Burgstaller, S. [et al]. (2013). Azacitidine in patients with WHO-defined AML: results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.Journal of Hematology & Oncology.April 29th2013;6(1):32. [Epub ahead of print].Full Text Link.

Liu, H.Zhai, X. Song, Z. [et al](2013).Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.Journal of Hematology & Oncology.February 8th2013;6:15.Full Text Link.

Gamazon, E.R. Lamba, J.K. Pounds, S. [et al]. (2013). Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.Blood. May 23rd2013;121(21):4366-76. Full Text Link.

Arlotta, A. Giuseppina, C.M. Palma, M. [et al]. (2013). Critical pulmonary infection due to nontuberculous mycobacterium in pediatric leukemia: report of a difficult diagnosis and review of pediatric series.Journal of Pediatric Hematology/Oncology.March 21st2013. [Epub ahead of print].

Kharfan-Dabaja, M.A. Hamadani, M. Reljic, T. [et al]. (2013). Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.British Journal of Haematology.August 23rd2013. [Epub ahead of print].

Leitch, H.A. Buckstein, R. Shamy, A. [et al]. (2013). The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.Critical Reviews in Oncology/Hematology.February 2013;85(2):162-92.

Guilhamon, P. Eskandarpour, M. Halai, D. [et al]. (2013). Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.Nature Communications.2013;4:2166.Full Text Link.

Chan, A. [and] Lo-Coco, F. (2013).Mitoxantrone-related acute leukemia in MS: an open or closed book?Neurology.April 16th2013;80(16):1529-33.

Parameswaran, R. Lim, M.Arutyunyan, A. [et al] (2013).O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.Journal of Experimental Medicine.April 8th2013;210(4):805-19. Full Text Link.

Zhu, HH. Wu, DP. Jin, J. [et al](2013).Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.Journal of Clinical Oncology.October 14th2013. [Epub ahead of print].

Guo, B. Liu, Y. Tan, X. [et al]. (2013). Prognostic significance of vascular endothelial growth factor expression in adult patients with acute myeloid leukemia: a meta-analysis.Leukemia and Lymphoma.July 2013;54(7):1418-25.

Bhojwani, D.Pui, CH. (2013).Relapsed childhood acute lymphoblastic leukaemia.The Lancet Oncology. May2013;14(6):e205-17.

Lo-Coco, F.Avvisati, G.Vignetti, M. [et al]; GruppoItalianoMalattieEmatologichedell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia (2013).Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.The New England Journal of Medicine.July 11th2013;369(2):111-21.

Richards, S. Pui, C.H. [and] Gayon, P.; Childhood Acute Lymphoblastic Leukemia Collaborative Group (CALLCG)(2013).Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.Pediatric Blood & Cancer.February 2013;60(2):185-95. Review.Full Text Link.

Maurillo, L. Buccisano, F. Del Principe, M.I. [et al]. (2013). Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Mediterranean Journal of Hematology and Infectious Diseases.June 3rd2013;5(1):e2013032. Full Text Link.

Anaemia

Chen, J. Lee, V.Luo, CJ. [et al](2013). Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group.British Journal of Haematology.August 2013;162(3):383-91.

Haider, B.A. Olofin, I. Wang, M. [et al]. (2013). Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ, 346, f3443.Full Text Link.

Babushok, D.V. Li, Y. Roth, J.J. [et al]. (2013). Common polymorphic deletion of glutathione S-transferase theta predisposes to acquired aplastic anemia: Independent cohort and meta-analysis of 609 patients.American Journal of Hematology.June 24th2013. [Epub ahead of print].

Badve, S.V. Beller, E.M. Cass, A. [et al]. (2013). Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database of Systematic Reviews (Online).August 26th2013; Issue 8: No. CD006861. Full Text Link.

Gafter-Gvili, A. Rozen-Zvi, B. Vidal, L. [et al]. (2013). Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia: systematic review and meta-analysis of randomised controlled trials.Acta Oncologica.January 2013;52(1):18-29. Full Text Link.

Antocoagulantsand Antiplatelet Drugs

Tantry, US.Bonello, L.Aradi, D. [et al] (2013).Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding.Journal of the American College of Cardiology.September 26th2013. [Epub ahead of print].

Brunetti, L. [and] Bandali, F. (2013).Dabigatran: is there a role for coagulation assays in guiding therapy? Annals of Pharmacotherapy. June 2013;47(6):828-40. Full Text Link.

Prins, MH.Lensing, AW.(2013). Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism.Thrombosis Journal.July 6th2013;11(1):13. Full Text Link.

Castellucci, L.A. Cameron, C. Le Gal, G. [et al]. (2013). Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.BMJ.August 30th2013;347:f5133. Full Text Link.

Makris, M. Van Veen, J.J. Tait, C.R. [et al]; British Committee for Standards in Haematology.(2013). Guideline on the management of bleeding in patients on antithrombotic agents.British Journal of Haematology.January 2013;160(1):35-46. Full Text Link.

Tahir, F.Riaz, H.Riaz, T. [et al] (2013).The new oral anti-coagulants and the phase 3 clinical trials: a systematic review of the literature.Thrombosis Journal.September 3rd2013;11(1):18. [Epub ahead of print].Full Text Link.

Saver, JL.Fonarow, GC. Smith, EE. [et al] (2013).Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.JAMA.June 19th2013;309(23):2480-8.

Tran, H.A. Chunilal, S.D. Harper, P.L. [et al]; Australasian Society of Thrombosis and Haemostasis (ASTH). (2013). An update of consensus guidelines for warfarin reversal.Medical Journal of Australia.March 4th2013;198(4):198-9. Full Text Link.

Chronic Leukaemia

Fabris, S. Mosca, L. Cutrona, G. [et al]. (2013). Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.American Journal of Hematology.January 2013;88(1):24-31. Full Text Link.

Oriana, C. Martin, H. Toby, P. [et al]. (2013). Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value in Health, 2013, 16(6), 1081-1090.

Baccarani, M.Deininger, MW.Rosti, G. [et al] (2013).European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Blood.August 8th2013;122(6):872-84. Full Text Link.

Gurion, R. Gafter-Gvili, A. Vidal, L. [et al]. (2013). Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.Haematologica.January 2013;98(1):95-102. Full Text Link.

Gotlib, J. Pardanani, A. Akin, C. [et al]. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Blood.March 28th2013;121(13):2393-401. Full Text Link.

Stauffer Larsen, T.Iversen, KF. Hansen, E. [et al] (2013).Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemiavera and myelofibrosis treated with recombinant interferon alpha.Leukemia Research.September 2013;37(9):1041-5.

Bixby, D.L. (2013). Managing inadequate responses to frontline treatment of chronic myeloid leukemia: a case-based review.Cancer Treatment Reviews. May2013;39(3):241-51. Review.

Maxson, JE.Gotlib, J.Pollyea, DA. [et al] (2013).Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.The New England Journal of Medicine. May 9th2013;368(19):1781-90.

Nemunaitis, J.Mita, A. Stephenson, J. [et al]. (2013). Pharmacokinetic study of omacetaxinemepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.Cancer Chemotherapy and Pharmacology.January 2013;71(1):35-41. Full Text Link.

Stein, AM. Martinelli, G. Hughes, TP. [et al] (2013).Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.BMC Cancer.April 2nd2013;13(1):173. [Epub ahead of print].Full Text Link.

Mealing, S.Barcena, L. Hawkins, N. [et al](2013).The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.ExperimentalHematology and Oncology.February 19th2013;2(1):5. Full Text Link.

Ross, DM. Branford, S. Seymour, JF. [et al] (2013).Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.Blood.July 25th2013;122(4):515-22. Full Text Link.

Touw, IP.Beekman, R. (2013). Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.Haematologica.October 2013;98(10):1490-2. Full Text Link.

Ahmed, W. [and] Van Etten, R.A. (2013).Signal transduction in the chronic leukemias: implications for targeted therapies.Current Hematologic Malignancy Reports.March 2013; 8(1), 71-80.

Breccia, M. Salaroli, A. Molica, M. [et al].(2013). Systematic review of dasatinib in chronic myeloid leukemia.OncoTargets and Therapy. 2013;6:257-65. Full Text Link.

Byrd, JC.Furman, RR.Coutre, SE. [et al] (2013).Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.The New England Journal of Medicine.July 4th2013;369(1):32-42.

Haemophilia

Srivastava, A. Brewer, A.K. Mauser-Bunschoten, E.P. [et al]; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. (2013). Guidelines for the management of hemophilia.Haemophilia.January 2013;19(1):e1-47. Full Text Link.

Baumann Kreuziger, L.M. Morton, C.T. [and] Reding, M.T. (2013). Is prophylaxis required for delivery in women with factor VII deficiency?Haemophilia.April 22nd2013. [Epub ahead of print].

Ragni,MV.Novelli, EM.Murshed, A. [et al] (2013). Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.Thrombosis and Haemostasis. February 2013;109(2):248-54. Full Text Link.

Franchini, M. Coppola, A. Rocino, A. [et al]; on behalf of the Italian Association of Hemophilia Centers (AICE) Working Group (2013).Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update.Seminars in Thrombosis and Hemostasis.September 10th2013. [Epub ahead of print].

Lymphoma

Itchaki, G. Gafter-Gvili, A. Lahav, M. [et al].(2013). Anthracycline-containing regimens for treatment of follicular lymphoma in adults.Cochrane Database of Systematic Reviews (Online).July 7th2013; Issue 7: No.CD008909. Full Text Link.

Allart, P.Soubeyran, P.Cousson-Gélie, F.(2013).Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature.Psychooncology.February 2013;22(2):241-9. Review.

Borchiellini, D.Ghibaudo, N.Mounier, N. [et al](2013).Blastic plasmacytoid dendritic cell neoplasm: a report of four cases and review of the literature.Journal of the European Academy of Dermatology and Venereology.September 2013;27(9):1176-81.

Dunleavy, K.Pittaluga, S. Maeda, LS. [et al] (2013).Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.The New England Journal of Medicine.April 11th2013;368(15):1408-16. Full Text Link.

Delarue, R. Tilly, H. Mounier, N. [et al]. (2013). Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.Lancet Oncology. May2013;14(6):525-33.

Skoetz, N.Trelle, S.Rancea, M. [et al] (2013).Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.The Lancet Oncology.September 2013;14(10):943-52.

El-Jurdi, N. Reljic, T. Kumar, A. [et al].(2013). Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.Immunotherapy. May2013;5(5):457-66

Ghielmini, M. Vitolo, U. Kimby, E. [et al]; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma (2013).ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Annals of Oncology.March 2013;24(3):561-76. Full Text Link.

Copie-Bergman, C. Wotherspoon, A.C. Capella, C. [et al]. (2013). Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice.British Journal of Haematology.January 2013;160(1):47-52.

Cao, H.Y. Zou, P. [and] Zhou, H. (2013).Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene. May 1st2013;519(2):288-94.

Eich, H.T. Kriz, J. Schmidberger, H. [et al]; Deutsche GesellschaftfürHämatologie und MedizinischeOnkologie (DGHO).(2013). The German evidence-based guidelines for Hodgkin's lymphoma.Aspects for radiation oncologists.Strahlentherapie und Onkologie.June 2013;189(6):445-7.

Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.Cochrane Database of Systematic Reviews (Online).June 20th2013; Issue 6: No.CD009411. Full Text Link.

Hoppe, R.T. Advani, R.H. Ai, W.Z. [et al]. (2012). Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, May 2013, 10(5), 589-597.Full Text Link.

Bachy, E. Houot, R. Morschhauser, F. Groupe d'Etude des Lymphomes de l'Adulte (GELA).(2013).Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Haematologica.July 2013;98(7):1107-14. Full Text Link.

Specht, L.Yahalom, J.Illidge, T. [et al]; ILROG (2013).Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).International Journal of Radiation Oncology, Biology, Physics.June 18th2013. [Epub ahead of print].

Song, S.X. Willemze, R. Swerdlow, S.H. [et al]. (2013). Mycosis fungoides: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop.American Journal of Clinical Pathology.April 2013;139(4):466-90. Full Text Link.

Mateos, MV. San Miguel, JF. (2013). New approaches to smoldering myeloma.Current Hematologic Malignancy Reports.August 23rd2013. [Epub ahead of print].

Matasar, MJ.Czuczman, MS. Rodriguez, MA. [et al] (2013).Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.Blood.July 25th2013;122(4):499-506. Full Text Link.

Daniels, L.A. Oerlemans, S. Krol, A.D. [et al]. (2013). Persisting fatigue in Hodgkin lymphoma survivors: a systematic review.Annals of Hematology.August 2013;92(8):1023-32. Review.

von Hohenstaufen, KA.Conconi, A. de Campos, CP. [et al] (2013).Prognostic impact of monocyte count at presentation in mantle cell lymphoma.British Journal of Haematology.August 2013;162(4):465-73.

vonHohenstaufen, KA.Conconi, A. de Campos, CP. [et al] (2013).Prognostic impact of monocyte count at presentation in mantle cell lymphoma.British Journal of Haematology.August 2013;162(4):465-73.

D'Cruz, O.J. [and] Uckun, F.M. (2013).Protein kinase inhibitors against malignant lymphoma.Expert Opinion on Pharmacotherapy.April 2013;14(6):707-21. Review.Full Text Link.

Zinzani, P.L. Marchetti, M. Billio, A. [et al]; Expert Panel of the Italian Society of Hematology. (2013). SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.American Journal of Hematology.March 2013;88(3):185-92.

Goy, A. Sinha, R. Williams, ME. [et al] (2013).Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) Study.Journal of Clinical Oncology.October 10th2013;31(29):3688-95.

Wang, ML. Rule, S. Martin, P. [et al] (2013).Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.The New England Journal of Medicine.August 8th2013;369(6):507-16.

Miscellaneous

Chan, L.L. Laverty, D.J. Smith, T. [et al].(2013). Accurate measurement of peripheral blood mononuclear cell concentration using image cytometry to eliminate RBC-induced counting error.Journal of Immunological Methods.February 28th2013;388(1-2):25-32.

Franchini, M. Frattini, F. Crestani, S. [et al]. (2013). Acquired FXIII inhibitors: a systematic review.Journal of Thrombosis and Thrombolysis.July 2013;36(1):109-14.

Gisslinger, H.Gotic, M.Holowiecki, J. [et al]; ANAHYDRET Study Group(2013).Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Blood.March 7th2013;121(10):1720-8. Full Text Link.

Sonnichsen, D.Dorer, DJ. Cortes, J. [et al] (2013).Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.Cancer Chemotherapy and Pharmacology.June 2013;71(6):1599-607. Full Text Link.

Jarvis, JN.Coltart, CE. Pule, M. [et al] (2013).Artemisinin therapy and severe delayed haemolysis.Lancet.July 13th2013; 382(9887):180.Full Text Link.

Fang, M. Zeng, W. Huang, L. [et al]. (2013). Association between glutathione S-transferase T1 null genotype and risk of myelodysplastic syndromes: a comprehensive meta-analysis.Tumour Biology. May 22nd2013. [Epub ahead of print].

Peinemann, F. Smith, L.A. [and] Bartel, C. (2013).Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.Cochrane Database of Systematic Reviews (Online).August 7th2013; Issue 8: No.CD008216. Full Text Link.

Costanzo, E.S. Juckett, M.B. [and] Coe, C.L. (2013).Biobehavioral influences on recovery following hematopoietic stem cell transplantation.Brain, Behavior, and Immunity.March 2013;30 Supplement:S68-74.Review.Full Text Link.

Duque, M. Modlin, I.M. Gupta, A. [et al]. (2013). Biomarkers in neuroendocrine tumors.JOP.July 10th2013;14(4):372-6. Full Text Link.

Mahaffey, KW.Wojdyla, D.Hankey, GJ. [et al] (2013).Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.Annals ofInternal Medicine.June 18th2013;158(12):861-8.

Marty, FM.Winston, DJ.Rowley, SD. [et al]; CMX001-201 Clinical Study Group (2013).CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.The New England Journal of Medicine.September 26th2013;369(13):1227-36.

Bath, P.M. Sprigg, N. [and] England, T. (2013).Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke.Cochrane Database of Systematic Reviews (Online) .June 24th2013; Issue 6: No.CD005207. Full Text Link.

Zsiros, J.Brugieres, L. Brock, P. [et al]; International Childhood Liver Tumours Strategy Group (SIOPEL) (2013).Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.The Lancet Oncology.August 2013;14(9):834-42. Full Text Link.

Abdullah, K. Kendzerska, T. Shah, P. [et al]. (2013). Efficacy of oral iron therapy in improving the developmental outcome of pre-school children with non-anaemic iron deficiency: a systematic review.Public Health Nutrition.August 2013;16(8):1497-506.

Bolton-Maggs, P.H. Davies, T. Poles, D. [et al]. (2013). Errors in anti-D immunoglobulin administration: retrospective analysis of 15 years of reports to the UK confidential haemovigilance scheme.BJOG.June 2013;120(7):873-8.

Anderst, J.D. Carpenter, S.L. [and] Abshire, T.C. Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics.(2013). Evaluation for bleeding disorders in suspected child abuse.Pediatrics.April 2013;131(4):e1314-22. Full Text Link.

Jadoul, P. [and] Kim, S.S. (2012).Fertility considerations in young women with hematological malignancies. Journal of Assisted Reproduction and Genetics, June 2012, 29(6), 479-487.Full Text Link.

Loren, A.W. Mangu, P.B. Beck, L.N. [et al]; American Society of Clinical Oncology. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Journal of Clinical Oncology.2013;31(19):2500-10. Review.Full Text Link.

Wikkelsø, A.Lunde, J.Johansen, M. [et al] (2013).Fibrinogen concentrate in bleeding patients.Cochrane Database Systematic Reviews.August 29th 2013;8:CD008864. Full Text Link.

Milkins, C. Berryman, J. Cantwell, C. [et al]. (2013). Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories.British Committee for Standards in Haematology. Transfusion Medicine, 2013, 23(1), 3-35. Full Text Link.

Hashmi, S.Oliva, JL.Liesveld, JL. [et al] (2013).The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation.Leukemia Research.September 2013;37(9):1052-6.

Aldasouqi, S. Sheikh, A. Klosterman, P. [et al]. (2013). Hypoglycemia in patients with diabetes who are fasting for laboratory blood tests: the Cape Girardeau Hypoglycemia En Route Prevention Program.Postgraduate Medicine.January 2013;125(1):136-43. Review.

Dubovsky, J.A. Beckwith, K.A. Natarajan, G. [et al]. (2013). Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.Blood.July 25th2013. [Epub ahead of print].Full Text Link.

Cunha, R. Loiseau, P. Ruggeri, A. [et al]. (2013). Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis.Bone Marrow Transplantation.August 19th2013.

Angastiniotis, M. VivesCorrons, J.L. Soteriades, E.S. [et al]. (2013). The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders.ScientificWorldJournal.2013;727905.Full Text Link.

McCanny, PJ.McCoy, S. Grant, T. [et al] (2013).Implementation of an evidence based guideline reduces blood tests and length of stay for the limping child in a paediatric emergency department.Emergency Medicine Journal.January 2013;30(1):19-23.

Kristensen, PL.Pedersen-Bjergaard, U.Kjær, TW. [et al]. (2013). Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with Type 1 diabetes mellitus: a randomized cross-over trial.PLoS One. 2013;8(4):e59672. Full Text Link.

Gotlib, J. Pardanani, A. Akin, C. [et al]. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Blood.March 28th2013;121(13):2393-401. Full Text Link.

Berg, RL. Shaw, GR. (2013). Laboratory evaluation for vitamin B12 deficiency: the case for cascade testing.Clinical Medicineand Research.February 2013;11(1):7-15. Full Text Link.

Haupt, R. Minkov, M. Astigarraga, I. [et al]; Euro Histio Network. (2013).Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatric Blood & Cancer.February 2013;60(2):175-84.

Wallace, W.H. Thompson, L. [and] Anderson, R.A; Guideline Development Group. (2013). Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance.BMJ. 2013 Mar 27;346:f1190. Full Text Link.

Du, K. Hu, Y. Wu, K. [et al]. (2013). Long-term outcomes of antithymocyte globulin in patients with hematological malignancies undergoing myeloablative allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Clinical Transplantation.March - April 2013;27(2):E91-E100.

Arends, M. van Dussen, L. Biegstraaten, M. [et al]. (2013). Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature.British Journal of Haematology.June 2013;161(6):832-42. Review.

Larsen, MT.Hother, C.Häger, M. [et al].(2013). MicroRNA profiling in human neutrophils during bone marrow granulopoiesis and in vivo exudation.PLoS One. 2013;8(3):e58454. Full Text Link.

Bosmann, M. [and] Ward, P.A. (2013).Modulation of inflammation by interleukin-27.Journal of Leukocyte Biology.July 31st2013. [Epub ahead of print].

Bench, A.J. White, H.E. Foroni, L. [et al].British Committee for Standards in Haematology.(2013). Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.British Journal of Haematology.January 2013;160(1):25-34. Full Text Link.

Stanworth, SJ.Estcourt, LJ.Powter, G. [et al]; TOPPS Investigators (2013).A no-prophylaxis platelet-transfusion strategy for hematologic cancers.The New England Journal of Medicine. May 9th2013;368(19):1771-80.

Campbell, A. Price, J. [and] Hiatt, W.R. (2013).Omega-3 fatty acids for intermittent claudication.Cochrane Database of Systematic Reviews (Online).July 4th2013; Issue 7: No.CD003833. Full Text Link.

Azoulay, E.Mokart, D.Pène, F. [et al] (2013).Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium: a groupe de rechercherespiratoire en réanimationonco-hématologique study.Journal of Clinical Oncology.August 1st2013;31(22):2810-8.

Ribas, A. Kefford, R. Marshall, M.A. [et al]. (2013). Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.Journal of Clinical Oncology.February 10th2013;31(5):616-22. Full Text Link.

Bemer, MJ.Sorror, M.Sandmaier, BM. [et al] (2013).A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Cancer Chemotherapy and Pharmacology.September 2013;72(3):607-18.

Krishnan, RM. Sullivan, JH.Carlsten, C. [et al] (2013).A randomized cross-over study of inhalation of diesel exhaust, hematological indices, and endothelial markers in humans.Particle and Fibre Toxicology.March 26th2013;10: 7.Full Text Link.

Drucker, A.M. Wu, S. Busam, K.J. [et al]. (2013). Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.European Journal of Haematology.February 2013;90(2):142-50. Review.

Funakoshi, T. Latif, A. [and] Galsky, M.D. (2013).Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.Cancer Treatment Reviews.November 2013;39(7):818-30.

Funakoshi, T. Latif, A. [and] Galsky, M.D. (2013).Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis.Critical Reviews in Oncology/Hematology.October 2013;88(1):30-41.

Vander Lugt, MT. Braun, TM.Hanash, S. [et al] (2013).ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.The New England Journal of Medicine.August 8th2013;369(6):529-39.

Hopewell, S. Omar, O. Hyde, C. [et al]. (2013). A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010.BMJ Open.May 2nd2013;3(5).Full Text Link.

Legendre, CM.Licht, C.Muus, P. [et al] (2013).Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.The New England Journal of Medicine.June 6th2013;368(23):2169-81.

Bazzan, M. Vaccarino, A. Stella, S. [et al]. (2013). Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort.Autoimmunity Reviews. June 2013;12(8):826-31

Cao Z, Bao M, Miele L, Sarkar FH, Wang Z, Zhou Q. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis.European Journal of Cancer.August 27th2013. [Epub ahead of print].

Myeloma / Multiple Myeloma

Bringhen, S. Mateos, M.V. Zweegman, S. [et al]. (2013). Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Haematologica.June 2013;98(6):980-7. Full Text Link.

Mellqvist, UH.Gimsing, P.Hjertner, O. [et al]; Nordic Myeloma Study Group (2013).Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.Blood.June 6th2013;121(23):4647-54. Full Text Link.

Kharfan-Dabaja, M.A. Hamadani, M. Reljic, T. [et al]. (2013). Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Journal of Hematology & Oncology.January 4th2013;6:2. Review.Full Text Link.

Buac, D. Shen, M. Schmitt, S. [et al].(2013). From Bortezomib to other Inhibitors of the proteasome and beyond.Current Pharmaceutical Design.2013;19(22):4025-38. Full Text Link.

Braggio, E. [and] AlbarracinGarramuno, F. (2013).[Genetic tools for risk-stratification in multiple myeloma].Medicina (Buenos Aires). 2013;73(4):369-75. Spanish.Full Text Link.

Mangiacavalli, S.Pochintesta, L.Pascutto, C.[et al]. (2013). Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.American Journal of Hematology.February 2013;88(2):102-6. Full Text Link.

Chen, C. Baldassarre, F. Kanjeekal, S. [et al]. (2013). Lenalidomide in multiple myeloma: a practice guideline.Current Oncology. April 2013;20(2):e136-49.Full Text Link.

Mateos, MV.Hernández, MT.Giraldo, P. [et al] (2013).Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.The New England Journal of Medicine.August 1st2013;369(5):438-47.

Mikhael, J.R. Dingli, D. Roy, V. [et al]. (2013). Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.Mayo Clinic Proceedings.April 2013;88(4):360-76.

Bianchi, G. [and] Ghobrial, I.M. (2013).Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Leukemia and Lymphoma.February 2013;54(2):229-41.

Delgado, M.D. Albajar, M. Gomez-Casares, M.T. [et al]. (2013). MYC oncogene in myeloid neoplasias.Clinical & Translational Oncology.February 2013;15(2):87-94.

Bin, Q. [and] Luo, J. (2013).Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review.Leukemia and Lymphoma.January 2013;54(1):14-20. Review.

Palumbo, A. Waage, A. Hulin, C. [et al]. (2013). Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Haematologica.January 2013;98(1):87-94. Full Text Link.

Armeson, K.E. Hill, E.G. [and] Costa, L.J. (2013).Tandem autologous vs. autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment.Bone Marrow Transplantation.April 2013;48(4):562-7.

Dolloff, N.G. [and] Talamo, G. (2013).Targeted therapy of multiple myeloma.Advances in Experimental Medicine and Biology.2013;779:197-221.

Felix, J. Aragao, F. Almeida, J.M. [et al]. (2013). Time-dependent endpoints as predictors of overall survival in multiple myeloma.BMC Cancer. 2013 Mar 16;13:122. doi: 10.1186/1471-2407-13-122. Full Text Link.

Non-Hodgkin's Lymphoma

Bellera, C. Praud, D. Petit-Moneger, A. [et al]. (2013). Barriers to inclusion of older adults in randomised controlled clinical trials on Non-Hodgkin's lymphoma: a systematic review.Cancer Treatment Reviews.November 2013;39(7):812-7.

Carlesimo, M. Narcisi, A. Rossi, A. [et al]. (2013). Cutaneous manifestations of systemic non-Hodgkin lymphomas (NHL): study and review of literature.Journal of the European Academy of Dermatology and Venereology.June 24th2013. [Epub ahead of print].

Chen, G.C. Lv, D.B. Pang, Z. [et al]. (2013). Fruits and vegetables consumption and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies.International Journal of Cancer.July 2013;133(1):190-200.

Dalia, S. Chavez, J. Castillo, J.J. [et al]. (2013). Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies.Leukemia Research.September 2013;37(9):1107-15.

Rancea, M. Will, A. Borchmann, P. [et al]. (2013). Fifteenth Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Non-Hodgkin's Lymphoma.Journal of the National Cancer Institute.August 7th2013;105(15):1159-70. Full Text Link.

Derenzini, E. Casadei, B. Pellegrini, C. [et al]. (2013). Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.Clinical Lymphoma, Myeloma & Leukemia.June 2013;13(3):258-65.

Azmi, A.S. Al-Katib, A. Aboukameel, A. [et al].(2013). Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.Haematologica.July 2013;98(7):1098-106.Full Text Link.

Vose, JM.Habermann, TM.Czuczman, MS. [et al] (2013).Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.British Journal of Haematology.September 2013;162(5):639-47.

Barta, S.K. Xue, X. Wang, D. [et al]. (2013). Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1,546 patients.Blood.September 6th2013. [Epub ahead of print].Full Text Link.

Neutropenia / Febrile Neutropenia

Chong, Y.Shimoda, S.Yakushiji, H. [et al]. (2013). Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.PLoS One. 2013;8(1):e54190. Full Text Link.

Flowers, C.R. Seidenfeld, J. Bow, E.J. [et al]. (2013). Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.Journal of Clinical Oncology.February 20th2013;31(6):794-810. Full Text Link.

Paul, M. Dickstein, Y. Schlesinger, A. [et al]. (2013). Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.Cochrane Database of Systematic Reviews (Online).June 29th2013; Issue 6: No.CD003038. Full Text Link.

Wright, JD.Neugut, AI. Ananth, CV. [et al] (2013).Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes.JAMA Internal Medicine.April 8th2013;173(7):559-68. Full Text Link.

Pechlivanoglou, P. Le, H.H. Daenen, S. [et al]. (2013). Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.Journal of Antimicrobial Chemotherapy.August 23rd2013. [Epub ahead of print].Full Text Link.

Bate, J. Gibson, F. Johnson, E. [et al]. (2013). Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151).Archives of Disease in Childhood: Education and Practice Edition. April 2013;98(2):73-5.Full Text Link.

Haeusler, G.M. Carlesse, F. [and] Phillips, R.S. (2013).An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer.Pediatric Infectious Disease Journal. May 13th2013. [Epub ahead of print].

Other Infections

Chou, R. [and] Wasson, N. (2013).Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.Annals of Internal Medicine.June 4th2013;158(11):807-20. Full Text Link.

Drgona, L. Khachatryan, A. Stephens, J. [et al]. (2013). Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.European Journal of Clinical Microbiology and Infectious Diseases.September 12th2013. [Epub ahead of print].Full Text Link.

Deen, J. von Seidlein, L. Andersen, F. [et al]. (2012). Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infectious Diseases, June 2013, 12(6), 480-487.

Chou, R. Hartung, D. Rahman, B. [et al]. (2013). Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Annals of Internal Medicine, 158(2), 114-123.Full Text Link.

Harrison, D.Muskett, H. Harvey, S. [et al].(2013). Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.Health Technology Assessment.February 2013;17(3):1-156.

Emery, V. Zuckerman, M. Jackson, G. [et al]; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation; UK Virology Network.(2013). Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Journal of Haematology.July 2013;162(1):25-39. Full Text Link.

Chang, S.S. Hsieh, W.H. Liu, T.S. [et al]. (2013). Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis.PLoS One. May 29th2013;8(5):e62323. Full Text Link.

Neumann, S. Krause, S.W. Maschmeyer, G. [et al]; Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO).Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (2013). Annals of Hematology.April 2013;92(4):433-42. Review.Full Text Link.

Bhatt, AS. Freeman, SS. Herrera, AF. [et al] (2013).Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome.The New England Journal of Medicine.August 8th 2013;369(6):517-28.

Holst, LB.Haase, N.Wetterslev, J. [et al] (2013).Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU: protocol for a randomised controlled trial.Trials. May 23rd2013;14:150. Full Text Link.

Sickle Cell Anaemia & Thalassemia

Musallam, K.M. Taher, A.T. Cappellini, M.D. [et al]. (2013). Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.Blood.March 21st2013;121(12):2199-212; quiz 2372. Review.Full Text Link.

Fisher, S.A. Brunskill, S.J. Doree, C. [et al].(2013). Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.Cochrane Database of Systematic Reviews (Online).August 21st2013; Issue 8: No.CD004450. Full Text Link.

Mulaku, M. Opiyo, N. Karumbi, J. [et al].(2013). Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.Archives of Disease in Childhood.August 30th2013. [Epub ahead of print].Full Text Link.

Fisher, S.A. Brunskill, S.J. Doree, C. [et al].(2013). Oral deferiprone for iron chelation in people with thalassaemia.Cochrane Database of Systematic Reviews (Online).August 21st2013; Issue 8: No.CD004839. Full Text Link.

Oniyangi, O. [and] Cohall, D.H. (2013).Phytomedicines (medicines derived from plants) for sickle cell disease.Cochrane Database of Systematic Reviews (Online).January 31st2013; Issue 1: No.CD004448. Full Text Link.

Aneni, E.C. Hamer, D.H. [and] Gill, C.J. (2013).Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.Tropical Medicine and International Health.March 2013;18(3):313-27. Review.Full Text Link.

Jordan, L. Swerdlow, P. [and] Coates, T.D. (2013).Systematic review of transition from adolescent to adult care in patients with sickle cell disease.Journal of Pediatric Hematology/Oncology.April 2013;35(3):165-9. Review.

Howard, J.Malfroy, M.Llewelyn, C. [et al] (2013).The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.Lancet.March 16th2013;381(9870):930-8. Full Text Link.

Thrombocytopenia

Butler, C. Doree, C. Estcourt, L.J. [et al]. (2013). Pathogen-reduced platelets for the prevention of bleeding.Cochrane Database of Systematic Reviews (Online).March  28th 2013; Issue 3: No. CD009072. Review.Full Text Link.

Catalá-López, F. Corrales, I. Martín-Serrano, G. [et al].(2013). Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.MedicaClinica. October 20th2012;139(10):421-9. Review.

Rodeghiero, F. Michel, M. Gernsheimer, T. [et al]. (2013). Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.Blood.April 4th2013;121(14):2596-606. Full Text Link.

Avila, M.L. Shah, V. [and] Brandao, L.R. (2013).Systematic review on heparin-induced thrombocytopenia in children: a call to action.Journal of Thrombosis and Haemostasis.April 2013;11(4):660-9.

Wandt, H.Schaefer-Eckart, K.Wendelin, K. [et al]. (2013). Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.Lancet.October 13th2012;380(9850):1309-16. Full Text Link.

Stanworth, S.J. Walsh, T.S. Prescott, R.J. [et al]; Intensive Care Study of Coagulopathy Investigators. (2013).Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study.Transfusion. May2013;53(5):1050-8.

Kahn, M.J. Maley, J.H. Lasker, G.F. [et al]. (2013). Updated role of nitric oxide in disorders of erythrocyte function.Cardiovascular & Hematological Disorders Drug Targets.March 1st2013;13(1):83-7. Review.Full Text Link.

VTE

Garcia, D. Akl, E.A. Carr, R. [et al]. (2013). Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review.Blood.August 1st2013;122(5):817-24. Full Text Link.

Agnelli, G.Buller, HR. Cohen, A. [et al]; PLIFY-EXT Investigators (2013).Apixaban for extended treatment of venous thromboembolism.The New England Journal of Medicine.February 21st2013;368(8):699-708.

Hokusai-VTE, Investigators.Büller, HR.Décousus, H. [et al] (2013).Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.The New England Journal of Medicine.October 10th2013;369(15):1406-15.

Schulman, S.Kearon, C.Kakkar, AK. [et al]; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators (2013).Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.The New England Journal of Medicine.February 21st2013;368(8):709-18.

Farge, D. Debourdeau, P. Beckers, M. [et al].(2013). International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Journal of Thrombosis and Haemostasis.January 2013;11(1):56-70. Review.Full Text Link.

Aikens, G.B. Rivey, M.P. [and] Hansen, C.J. (2013).Primary venous thromboembolism prophylaxis in ambulatory cancer patients.Annals of Pharmacotherapy.February 2013;47(2):198-209. Review.Full Text Link.

Goldstein, P.Elalamy, I. Huber, K. [et al] (2013).Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism.International Journal of Emergency Medicine.July 16th2013;6(1):25. Full Text Link.

Jacobson, B.F. Louw, S. Buller, H. [et al]; South African Society of Thrombosis and Haemostasis. (2013). Venous thromboembolism: prophylactic and therapeutic practice guideline.South African Medical Journal.February 15th2013;103(4 Pt 2):261-7. Full Text Link.

Lyman, G.H. Khorana, A.A. Kuderer, N.M. [et al]. (2013). Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Journal of Clinical Oncology.June 10th2013;31(17):2189-204. Full Text Link.

International Guidelines & Guideline-Related (During the Previous Year)

Flowers, C.R. Seidenfeld, J. Bow, E.J. [et al]. (2013). Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.Journal of Clinical Oncology.February 20th2013;31(6):794-810. Full Text Link.

Engelbrecht, S. Wood, E.M. [and] Cole-Sinclair, M.F. (2013).Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards.Medical Journal of Australia.September 16th2013;199(6):397-401. Full Text Link.

Dignan, FL. Clark, A.Amrolia, P. [et al]; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation.(2012).Diagnosis and management of acute graft-versus-host disease.(2012).British Journal of Haematology.July 2012;158(1):30-45. Full Text Link.

Dignan, FL.Amrolia, P. Clark, A. [et al]; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation.(2012).Diagnosis and management of chronic graft-versus-host disease.British Journal of Haematology.July 2012;158(1):46-61. Full Text Link.

Baccarani, M.Pileri, S.Steegmann, JL. [et al]; ESMO Guidelines Working Group. (2012) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of Oncology.October 2012;23 Supplement 7:vii72-7. Full Text Link.

Bosnjak, B. Culjak-Aleksic, M. Gojceta, K. [et al]. (2012). [Croatian Society for Haematology and Transfusion Medicine Guidelines on the diagnosis and management of heparin induced thrombocytopenia (HIT)].LijecnickiVjesnik. September – October 2012;134(9-10):253-8.

Tilly, H. Vitolo, U. Walewski, J. [et al]; ESMO Guidelines Working Group. (2012). Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of Oncology.October 2012;23 Supplement 7:vii78-82. Full Text Link.

Baglin, T. Keeling, D. [and] Kitchen, S. (2012). Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.British Journal of Haematology.November 2012;159(4):427-9. Full Text Link.

Ullmann, A.J. Akova, M. Herbrecht, R. [et al]; ESCMID Fungal Infection Study Group.ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). (2012). Clinical Microbiology and Infection.December 2012;18 Supplement 7:53-67.

Ghielmini, M. Vitolo, U. Kimby, E. [et al]; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma (2013).ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Annals of Oncology.March 2013;24(3):561-76. Full Text Link.

Loren, A.W. Mangu, P.B. Beck, L.N. [et al]; American Society of Clinical Oncology. (2013). Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Journal of Clinical Oncology.2013;31(19):2500-10. Review.Full Text Link.

Eich, H.T. Kriz, J. Schmidberger, H. [et al]; Deutsche GesellschaftfürHämatologie und MedizinischeOnkologie (DGHO).(2013). The German evidence-based guidelines for Hodgkin's lymphoma.Aspects for radiation oncologists.Strahlentherapie und Onkologie.June 2013;189(6):445-7.

Reilly, J.T. McMullin, M.F. Beer, P.A. [et al]; Writing group: British Committee for Standards in Haematology. (2012). Guideline for the diagnosis and management of myelofibrosis.British Journal of Haematology.August 2012;158(4):453-71. Full Text Link.

Oscier, D. Dearden, C. Eren, E. [et al]; British Committee for Standards in Haematology.(2012). Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.British Journal of Haematology.December 2012;159(5):541-64. Full Text Link.

Srivastava, A. Brewer, A.K. Mauser-Bunschoten, E.P. [et al]; Treatment Guidelines Working Group on Behalf of the World Federation Of Hemophilia. (2013). Guidelines for the management of hemophilia.Haemophilia.January 2013;19(1):e1-47. Full Text Link.

Watson, H. Davidson, S. [and] Keeling, D.; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology.(2012). Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition.British Journal of Haematology.December 2012;159(5):528-40. Full Text Link.

Scully, M. Hunt, B.J. Benjamin, S. [et al]; British Committee for Standards in Haematology.(2012). Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.British Journal of Haematology.August 2012;158(3):323-35. Full Text Link.

Remacha, A. Sanz, C. Contreras, E. [et al]; Spanish Society of Blood Transfusion; Spanish Society of Haematology and Haemotherapy.(2013). Guidelines on haemovigilance of post-transfusional iron overload.Blood Transfusion.TrasfusionedelSangue. January 2013;11(1):128-39. Review.Full Text Link.

Thomas, D.W. Hinchliffe, R.F. Briggs, C. [et al]; British Committee for Standards in Haematology.(2013).Guideline for the laboratory diagnosis of functional iron deficiency.British Journal of Haematology.June 2013;161(5):639-48. Full Text Link.

Makris, M. Van Veen, J.J. Tait, C.R. [et al]; British Committee for Standards in Haematology.(2013). Guideline on the management of bleeding in patients on antithrombotic agents.British Journal of Haematology.January 2013;160(1):35-46. Full Text Link.

Lehrnbecher, T. Phillips, R. Alexander, S. [et al]; International Pediatric Fever and Neutropenia Guideline Panel. (2012). Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation.Journal of Clinical Oncology.December 10th2012;30(35):4427-38.Full Text Link.

Milkins, C. Berryman, J. Cantwell, C. [et al].(2013). Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories.British Committee for Standards in Haematology.Transfusion Medicine.February 2013;23(1):3-35. Full Text Link.

Gibellini, D. De Crignis, E. [and] Re, M.C. (2012).Guidelines for the qualitative detection of viral genomes in dried blood spots. Methods in Molecular Biology, 903, 21-34.

Hoppe, R.T. Advani, R.H. Ai, W.Z. [et al]. (2012). Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, May 2013, 10(5), 589-597.Full Text Link.

Leitch, H.A. Buckstein, R. Shamy, A. [et al]. (2013). The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.Critical Reviews in Oncology/Hematology.February 2013;85(2):162-92.

Farge, D. Debourdeau, P. Beckers, M. [et al].(2013). International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.Journal of Thrombosis and Haemostasis.January 2013;11(1):56-70. Review.Full Text Link.

Gotlib, J. Pardanani, A. Akin, C. [et al]. (2013). International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Blood.March 28th2013;121(13):2393-401. Full Text Link.

Haupt, R. Minkov, M. Astigarraga, I. [et al]; Euro Histio Network. (2013).Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatric Blood & Cancer.February 2013;60(2):175-84.

Chen, C. Baldassarre, F. Kanjeekal, S. [et al]. (2013). Lenalidomide in multiple myeloma: a practice guideline.Current Oncology. April 2013;20(2):e136-49.Full Text Link.

Wallace, W.H. Thompson, L. [and] Anderson, R.A; Guideline Development Group. (2013). Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance.BMJ. 2013 Mar 27;346:f1190. Full Text Link.

Perez Fidalgo, J.A. Garcia Fabregat, L. Cervantes, A. [et al]. (2012). Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology, 23 Supplement 7, vii167-173.Full Text Link.

Perez Fidalgo, J.A. Garcia Fabregat, L. Cervantes, A. [et al]; ESMO Guidelines Working Group. (2012). Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.European Journal of Oncology Nursing.December 2012;16(5):528-34.

Emery, V. Zuckerman, M. Jackson, G. [et al]; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation; UK Virology Network.(2013). Management of cytomegalovirus infection in haemopoietic stem cell transplantation.Journal of Haematology.July 2013;162(1):25-39. Full Text Link.

Mikhael, J.R. Dingli, D. Roy, V. [et al]. (2013). Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.Mayo Clinic Proceedings.April 2013;88(4):360-76.

Bench, A.J. White, H.E. Foroni, L. [et al].British Committee for Standards in Haematology.(2013). Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.British Journal of Haematology.January 2013;160(1):25-34. Full Text Link.

Bate, J. Gibson, F. Johnson, E. [et al]. (2013). Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151).Archives of Disease in Childhood: Education and Practice Edition. April 2013;98(2):73-5.Full Text Link.

Dignan, FL.Scarisbrick, JJ.Cornish, J. [et al]; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation.(2012).Organ-specific management and supportive care in chronic graft-versus-host disease.(2012).British Journal of Haematology.July 2012;158(1):62-78. Full Text Link.

Winters, J.L. (2012).Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology: The Education Program of the American Society of Hematology, 2012, 7-12.Full Text Link.

Neumann, S. Krause, S.W. Maschmeyer, G. [et al]; Infectious Diseases Working Party (AGIHO); German Society of Hematology and Oncology (DGHO).Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (2013). Annals of Hematology.April 2013;92(4):433-42. Review.Full Text Link.

Zinzani, P.L. Marchetti, M. Billio, A. [et al]; Expert Panel of the Italian Society of Hematology. (2013). SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.American Journal of Hematology.March 2013;88(3):185-92.

Barosi, G.Merlini, G.Billio, A. [et al] (2012).SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.Annals of Hematology.June 2012;91(6):875-88. Review.

Munoz Langa, J. Gascon, P. [and] de Castro, J.; SEOM (Spanish Society of Clinical Oncology).(2012). SEOM clinical guidelines for myeloid growth factors.Clinical & Translational Oncology.July 2012;14(7):491-8.

Tran, H.A. Chunilal, S.D. Harper, P.L. [et al]; Australasian Society of Thrombosis and Haemostasis (ASTH). (2013). An update of consensus guidelines for warfarin reversal.Medical Journal of Australia.March 4th2013;198(4):198-9. Full Text Link.

Validation of cell-based fluorescence assays: Practice guidelines from the International Council for Standardization of Haematology and International Clinical Cytometry Society. Cytometry, Part B: Clinical Cytometry, 2013, 84(5), 281. Full Text Link.

Jacobson, B.F. Louw, S. Buller, H. [et al]; South African Society of Thrombosis and Haemostasis. (2013). Venous thromboembolism: prophylactic and therapeutic practice guideline.South African Medical Journal.February 15th2013;103(4 Pt 2):261-7. Full Text Link.

Lyman, G.H. Khorana, A.A. Kuderer, N.M. [et al]. (2013). Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.Journal of Clinical Oncology.June 10th2013;31(17):2189-204. Full Text Link.

Recent NICE Guidelines  etc. (During the Previous Year)

NICE (2013). Diagnosis and management of venous thromboembolic diseases.Quality Standard QS29.London: National Institute for Health and Care Excellence (NICE), March 2013. Full Text Link.

NICE (2013). Hyperphosphataemia in chronic kidney disease.Clinical guideline CG157.London: National Institute for Health and Care Excellence (NICE), March 2013. Full Text Link.

NICE (2012). Leukaemia (acute myeloid ): decitabine (terminated appraisal) (TA270). Technology appraisalTA270: Terminated. London: National Institute for Health and Care Excellence (NICE), December 2012. Full Text Link.

Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib (TA251).Technology appraisalTA251.London: National Institute for Health and Care Excellence (NICE), April 2012. Full Text Link.

NICE (2013). Myelofibrosis (splenomegaly, symptoms):ruxolitinib (TA289). Technology Appraisal TA289.London: National Institute for Health and Care Excellence (NICE),June 26th2013. Full Text Link.

NICE (2012). Neutropenic sepsis (CG151).London: National Institute for Health and Care Excellence (NICE),September 19th2012. Full Text Link.

NICE (2012). Sickle cell acute painful episode (CG143).London: National Institute for Health and Care Excellence (NICE), June 27th2012.Full Text Link.

NICE (2013).Supporting the commissioning of anticoagulation therapy for adults.Commissioning Guidance CMG49.London: National Institute for Health and Care Excellence (NICE), May 14th2013.
Full Text Link

NICE (2013). Thrombocytopenic purpura: eltrombopag (TA293).Technology Appraisal TA293.London: National Institute for Health and Care Excellence (NICE),July 24th2013. Full Text Link.

NICE (2013).Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): appraisal consultation document 2. Consultation.London: National Institute for Health and Care Excellence (NICE), October 2013. Full Text Link.

NICE (2012). Venous thromboembolic diseases (CG144).Clinical guideline CG144.London: National Institute for Health and Care Excellence (NICE), June 27th2012.Full Text Link.

NICE (2012). Venous thromboembolism (treatment and long term secondary prevention): rivaroxaban (TA261).Technology appraisal TA261.London: National Institute for Health and Care Excellence (NICE), July 25th2012. Full Text Link.

New Books Available at HEFT Libraries

Moini, J. 2013. Phlebotomy: principles and practice, Burlington: Jones and Bartlett

Blaney, KD & Howard, PR. 2013. Basic & applied concepts of blood banking and transfusion practices, St. Louis, Mo: Mosby.

 If you would like to reserve any of the above books, please go to www.base-library.nhs.uk [You will need your Library card number to place a hold]

HEFT Libraries- Good Hope, Heartlands and Solihull

Mobile Apps

The libraries facilitate access to NICE, BNF and Cochrane Library apps for your phone or tablet via your Athens password. These can be downloaded from the Apple App Store or Google Play.

ASK your local library if you need support:

[email protected]

[email protected]

[email protected]

Topic of the Month

The topic of the month on display in the libraries across the sites for the November is Diabetes. Visit your local library to see the display. You can also visit the International Diabetes Federation to find out more.

Struggling with Referencing?

Use Refworks when researching your assignments to organise your citations. RefWorks is available through your Athens Login. Or contact our Faculty Training Librarian, Laura Walsh for a 1-2-1 or group session [email protected]

HEFT Repository

If you have published any article as part of your role in the Trust, please email the details to [email protected] . You can ‘browse’ the repository at www.repository.heartofengland.nhs.ukor via the HEFT Library website.

                                                                 Information Skills Training

This month HEFT Library Services are offering training sessions on Searching Healthcare Databases and Introduction to Critical Appraisal across all the sites. To book a place, please contact Laura Walsh-Faculty Training Librarian on 0121 424 0583 or [email protected]                                                 

                                                                       

 

 

Visit www.heftlibrary.nhs.uk for more information about the services the library provides or to request a literature search. Scan the QR code if you‘re reading a printout of this newsletter to jump to the site.                                                       

 

This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/